A chronic neurological condition that causes sudden, uncontrollable episodes of deep sleep and extreme daytime drowsiness, like a phone that unexpectedly shuts off during the day. It matters to investors because it defines the market need for treatments, influences clinical trial results and regulatory decisions, and can drive revenue or risk for companies developing medications, devices, or diagnostics tied to sleep disorders.
idiopathic hypersomniamedical
A chronic sleep disorder that causes extreme daytime sleepiness and prolonged, unrefreshing sleep despite adequate night sleep, with no identifiable medical or neurological cause. Think of it like a phone battery that won’t hold charge: sufferers remain tired and less productive even after long rest. For investors, idiopathic hypersomnia matters because it creates demand for treatments, diagnostics and supportive services, influencing market opportunities and regulatory pathways in sleep medicine.
randomized clinical trialsmedical
A randomized clinical trial is a medical study where participants are randomly assigned to different treatments or a control so the effectiveness and safety of a drug or procedure can be measured without bias. Think of it like flipping a coin to decide who gets which option so outcomes reflect the treatment, not who was chosen. Investors watch these trials because their results strongly influence regulatory approval, market demand and a company’s future revenue and risk profile.
phase 3 trialmedical
A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.
A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.
gastro-resistant formulationmedical
A gastro-resistant formulation is a pill or capsule designed with a protective coating that keeps the medicine from dissolving in the acidic environment of the stomach and instead releases it later in the intestines. For investors, this matters because it can improve a drug’s effectiveness, reduce stomach-related side effects, enable different dosing schedules, and extend product differentiation or patent strategies—like giving a product a built-in delivery advantage over competitors.
phase 1bmedical
"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.
open-labelmedical
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD.
The poster presentation details are as follows:
Abstract Title
Poster Presentation Session
Treatment with Pitolisant in Subgroups of Adults with Narcolepsy: Pooled Analysis of Two Randomized Clinical Trials
P-16 (Poster #387), 6/15/2026, 10:00-10:45 a.m.
Effect of Pitolisant on Sleep Patterns in Idiopathic Hypersomnia: Analysis of Phase 3 Trial Sleep Diary Data
P-16 (Poster #378), 6/15/2026, 11:00-11:45 a.m.
Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia
P-1 (Poster #384), 6/15/2026, 11:00-11:45 a.m.
Pitolisant Gastro-Resistant Formulation (HBS-201) Dosing Optimization Study in Adults with Narcolepsy: Results from a Phase 1b Clinical Trial
P-41 (Poster #525), 6/16/2026, 10:00-10:45 a.m.
Patient Experience of Fatigue and Assessment in Narcolepsy: A Cross-Sectional Study
P-35 (Poster #330), 6/16/2026, 11:00-11:45 a.m.
Long-Term Safety and Effectiveness of Pitolisant in Adult Patients with Idiopathic Hypersomnia: Final Results From an Open-Label Phase 3 Trial
P-41 (Poster #524), 6/16/2026, 11:00-11:45 a.m.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
